focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksETX.L Share News (ETX)

  • There is currently no data for ETX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Virgin Wines warns sales will be below City forecasts

Thu, 04th May 2023 19:37

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

----------

Virgin Wines UK PLC - Norwich, England-based online wine retailer - Expects financial year 2023 sales to be slightly lower than market expectations, at around GBP60 million, with underlying pretax profit in the region of GBP500,000 to GBP1 million, with a profitable and cash generative fourth quarter. Thereafter, expects double digit sales growth in financial year 2024, alongside an earnings before interest, tax, depreciation and amortisation margin of around 4% to 5%, as inflationary pressures particularly on freight and glass start to ease. Reports fourth quarter trading is expected to be in line with the previous year, but adds the third quarter was affected by a reduction in order frequency through the WineBank customer membership, a period which saw an increasingly competitive environment. Encouragingly, points out cancellation and conversion rates have started to improve since the end of the first half whilst the trade rate has also recovered from its low point in November 2022.

----------

Pollen Street PLC - London, England-based asset manager - Reports net asset value at March 31 was 900 pence or GBP578 million while its tangible net asset value per share was 540p or GBP347 million. No comparison given. Says assets under management remained at GBP3.4 billion while average fee-paying AUM continued to build to GBP2.5 billion in the first quarter, up from GBP2.3 billion for 2022. Declares a dividend of 16p.

----------

Hansard Global PLC - Isle of Man-based long-term savings provider - Issues trading update for the third quarter to March 31. Says new business was GBP25.4 million, ahead of GBP18.6 million in the previous quarter and down from GBP31.4 million a year prior. Assets under administration were GBP1.12 billion, up GBP15.6 million from the end of December. Continues to make encouraging progress with distribution opportunities for its Japanese proposition, company states. Adds new business in its largest region, Middle East and Africa, rose 20.8%, while in Latin America new business was down 9.5%.

----------

Forward Partners Group PLC - London-based early-stage technology-focused investor - Reports revenue in the year to December 31 of GBP509,000 down from GBP826,000 a year prior with a pretax loss of GBP43.1 million compared to a profit of GBP16.5 million. Net asset value at period end was 72 pence down from 104p a year before. Remains confident that healthy returns can be generated from the investment in early-stage UK startups over the long-term.

----------

e-Therapeutics PLC - Oxford, England-based computer-based drug discovery company - Reports pretax loss in the year to January 31 of GBP9.8 million widened from GBP9.5 million a year before on broadly unchanged revenue of GBP475,000 compared to GBP477,000. Basic and diluted earnings per share was 1.54 pence compared to 1.65p. Says well-positioned to advance pipeline of first-in-class preclinical RNAi candidates across multiple therapeutic areas, making significant progress in just one year. Notes increased losses mainly attributable to increased R&D expenditure reflecting further progress and development of its business strategy. Explains company has sufficient funds to continue in operational existence for at least 12 months from the signing of these financial statements.

----------

Let's Explore Group PLC - Manchester, England-based virtual reality entertainment company, formerly called Immotion Group PLC - Reports pretax loss from continuing operations in the year to December 31 of GBP1.9 million widened from GBP1.8 million on reduced revenue of GBP796,000, down from GBP2.5 million. Basic loss per share totalled 0.46 pence compared to 0.43p a year prior. Says group revenue from total operations increased 23% to GBP11.6 million from GBP9.4 million while adjusted earnings before interest, tax, depreciation and amortisation from total operations rose 51% to GBP1.4 million from GBP0.9 million. Notes since the year end the group has sold its largest business, Location Based Entertainment for around USD25 million and a smaller subsidiary, Uvisan.

----------

By Jeremy Cutler, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
16 Oct 2013 11:57

UK WINNERS & LOSERS: Hargreaves Continues To Rise, e-Therapeutics Trips

Read more
16 Oct 2013 08:56

e-Therapeutics Pretax Loss Widens As R&D Expenditure Rises

Read more
30 Sep 2013 18:45

DIRECTOR DEALINGS: E-Therapeutics Exec, Wife Combined Shares Total 1.8M

Read more
24 Jul 2013 15:53

Wife of DS Smith CEO sells 5.6m-pound stake

The wife of DS Smith frontman Miles Roberts sold a substantial sum of shares in the packaging and office supplies firm on the same day it was revealed the Chief Executive Officer (CEO) received a big pay increase last year. The move came on Tuesday, the same day DS Smith released its annual report

Read more
14 May 2013 09:46

e-Therapeutics pleases with pipeline progress

News from biotech company e-Therapeutics about the progress of two clinical trials for its cancer drug pleased the markets on Tuesday. The AIM-listed company provided first findings for the company's ETS2101 drug candidate in Phase I trials in the US for patients with brain cancer and in the UK fo

Read more
14 May 2013 08:04

Tuesday broker round-up UPDATE

Babcock International: Jefferies increases target price from 1080p to 1250p and maintains a buy recommendation. Barratt Developments: Bank of America takes target price from 265p to 325p, while downgrading to neutral. Belgravium Technologies: WH Ireland places both its target price and its neutral

Read more
10 May 2013 07:14

Friday broker round-up UPDATE

Afren: Westhouse Securities initiates with a target price of 160p and a buy recommendation. Ashmore Group: Credit Suisse raises target price from 375p to 440p upgrading from underperform to neutral. Barratt Developments: Citigroup increases target price from 245p to 315p leaving its neutral rating

Read more
19 Feb 2013 16:21

Debenhams Executive Director adds to stake

Michael Sharp, the Executive Director of retail chain Debenhams, has topped up his stake in the group with the purchase of 50,000 shares. Sharp, who has been in his current role since September 2011, bought the shares at 97.20p for a total of £48,598. He now holds 6.2m shares in the company. Debe

Read more
11 Feb 2013 09:15

e-Therapeutics shares jump following 40m equity issue

Drug discovery and development company e-Therapeutics is proposing to raise 40m pounds through an issue of new ordinary shares to existing and new institutional investors. The new shares will be priced at 32p, a premium of 4.0% to the closing mid-market price on Friday. Following the proposed issu

Read more
23 Oct 2012 09:23

Tuesday broker round-up

Aggreko: UBS cuts target from 2,750p to 2,550p, buy rating kept. ARM Holdings: Investec keeps buy rating and 800p target. Avacta: Panmure Gordon keeps buy rating and 1.75p target. AZ Electronic: Canaccord Genuity ups target from 360p to 376p, buy rating kept. Babcock: JPMorgan Cazenove ups targe

Read more
22 Oct 2012 08:19

Monday broker round-up - UPDATE

888 Holdings: Morgan Stanley ups target from 125p to 130p, overweight rating kept. Aggreko: Jefferies cuts target from 2,800p to 2,535p, buy rating kept; HSBC downgrades to underweight, target cut from 2,350p to 1,750p; JPMorgan Cazenove cuts target from 2,360p to 2,165p, neutral rating kept; Barcl

Read more
22 Oct 2012 07:53

e-therapeutics produces mixed interims

e-therapeutics, a drug discovery and development company, produced mixed interims with slightly increased losses, but reported progress on its lead cancer drug. As expected, first half losses increased to £1.8m (2011: loss of £1.5m), reflecting increased investment in the business. The company ha

Read more
15 Mar 2011 17:05

Bramson vehicle buys more shares in F&C

F&C Asset Management chairman Edward Bramson's investment vehicle SIGA LP has acquired more shares in the asset management company. Bramson was appointed chairman of F&C last month after a shareholder coup removed the previous incumbent, along with another non-executive, and appointed three new di

Read more
14 Mar 2011 17:19

Wife of outgoing FD sells British Land shares

Diane Roberts, the wife of British Land finance director Graham Roberts, has raised more than £1m by selling more than three-quarters of the couple's stake in the property investor. She sold 191,780 shares at 562.8p each, which raised £1.08m. The couple are left with 50,464 shares in British Land.

Read more
4 Mar 2011 17:03

Shaftesbury boss invests £100,000

Shaftesbury chief executive Jonathan Lane has invested a further £100,000 in the property investor. Lane has bought 22,222 shares at 450p each. That takes his stake to 966,233 shares, which is worth £4.3m at the latest purchase price. Lane raised just over £99,000 from the sale of option shares la

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.